The ProtecT trial - evaluating the effectiveness of treatments for clinically localised prostate cancer

Citation
The ProtecT trial - evaluating the effectiveness of treatments for clinically localised prostate cancer. Health Technology Assessment

Authors' objectives
The overall aim is to evaluate the effectiveness, cost-effectiveness and acceptability of treatments for men with localised prostate cancer within the context of a pragmatic randomised controlled trial. This will compare 3 treatments (active monitoring, radical prostatectomy and radical radiotherapy). Specific objectives are as follows: 1) To assess survival at 5, 10 years and 15 years following treatment 2) To investigate a number of short and medium-term outcomes, including: disease progression (biochemical and clinical), treatment complications, lower urinary tract symptoms, psychosocial impact of case-finding and treatment, including generic health status, quality of life and sexual function 3) To estimate the resource use and costs of case-finding, treatment and follow-up, and to compare costs and outcomes of treatment in terms of survival and health related quality of life. 4) To collect material suitable for basic science research, and develop a network for collaborative research.

Project page URL
http://www.nets.nihr.ac.uk/projects/hta/962099

Final publication URL
http://www.epi.bris.ac.uk/protect

INAHTA brief and checklist

Indexing Status
Subject indexing assigned by CRD

MeSH
Clinical Trials as Topics; Prostatic Neoplasms

Language Published
English

Country of organisation
England

English summary
An English language summary is available.

Address for correspondence
NETSCC, Health Technology Assessment, Alpha House, University of Southampton Science Park, Southampton, SO16 7NS UK Tel: +44 23 8059 5586 Email: hta@hta.ac.uk

AccessionNumber
3201000393
Date abstract record published
28/04/2010